Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is 5.71x as of 2026-10-06T14:55:56.524Z.
Calculation as of: 2026-10-06T14:55:56.524Z.
Quote observation: 2026-10-06T14:55:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
5.71x
SECTOR MEDIAN · HEALTHCARE
1.52x
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
+275.66%
vs the sector median at left
Attovia Therapeutics, Inc.
Market Cap
$760.77M
EV/Assets Ratio
5.71x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$763.47M
EV/Assets Ratio
1.99x
TTM Avg
1.56x
3Y Avg
1.53x
5Y Avg
1.63x
Market Cap
$755.11M
EV/Assets Ratio
3.46x
TTM Avg
2.95x
3Y Avg
1.52x
5Y Avg
1.47x
Market Cap
$753.58M
EV/Assets Ratio
2.89x
TTM Avg
2.23x
3Y Avg
3.61x
5Y Avg
2.57x
Market Cap
$775.12M
EV/Assets Ratio
3.17x
TTM Avg
3.08x
3Y Avg
1.98x
5Y Avg
2.19x
Market Cap
$776.24M
EV/Assets Ratio
1.61x
TTM Avg
1.89x
3Y Avg
3.13x
5Y Avg
3.21x
Market Cap
$785.71M
EV/Assets Ratio
0.65x
TTM Avg
0.73x
3Y Avg
0.74x
5Y Avg
0.80x
Market Cap
$726.83M
EV/Assets Ratio
3.64x
TTM Avg
5.10x
3Y Avg
3.50x
5Y Avg
2.80x
Market Cap
$798.26M
EV/Assets Ratio
3.81x
TTM Avg
4.08x
3Y Avg
19.79x
5Y Avg
15.81x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $760.77M | 5.71x | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.47M | 1.99x | 1.56x | 1.53x | 1.63x |
| Design Therapeutics, Inc. (DSGN)vs › | $755.11M | 3.46x | 2.95x | 1.52x | 1.47x |
| Candel Therapeutics, Inc. (CADL)vs › | $753.58M | 2.89x | 2.23x | 3.61x | 2.57x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.12M | 3.17x | 3.08x | 1.98x | 2.19x |
| Geron Corporation (GERN)vs › | $776.24M | 1.61x | 1.89x | 3.13x | 3.21x |
| AdaptHealth Corp. (AHCO)vs › | $785.71M | 0.65x | 0.73x | 0.74x | 0.80x |
| Achieve Life Sciences, Inc. (ACHV)vs › | $726.83M | 3.64x | 5.10x | 3.50x | 2.80x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $798.26M | 3.81x | 4.08x | 19.79x | 15.81x |
| Avalo Therapeutics, Inc. (AVTX)vs › | $718.57M | 1.29x | 2.02x | 1.33x | 1.20x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
